BetterLife Pharma (TSE:BETR) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BetterLife Pharma Inc. has amended beneficial ownership information in past Management Information Circulars and announced the issuance of new shares and warrants following a convertible debentures conversion. The biotech company is advancing the development of non-hallucinogenic compounds, BETR-001 and BETR-002, aimed at treating various neuropsychiatric and neurological disorders.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.